TIDMABDX
Abingdon Health PLC
07 September 2021
Abingdon Health plc
("Abingdon" or "the Company")
Launch of Semi-Quantitative Accessory to AbC-19(TM)
To help indicate the strength of antibody response and possible
immunity
York, U.K. 7 September 2021: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, announces the launch, initially for
research use only, of a score-card product available alongside the
AbC-19(TM) rapid test, which provides a semi-quantitative result to
indicate the strength of antibody response and possible immunity.
This is achieved by the use of a simple line intensity score-card
as illustrated here which is available as an accessory to the
standard Lateral Flow device ("LFD") for research applications.
The AbC-19(TM) LFD produces a line in the presence of IgG
neutralising antibodies to the spike protein of the SARS-CoV-2
virus as are produced both after vaccination and natural infection.
The intensity of the line, which can be seen visually, is
proportional to the amount of these IgG neutralising antibodies
present in the finger-prick blood sample with higher levels of
antibodies producing a stronger test line. The use of the
score-card has been referred to in studies, including one from the
University of Birmingham, illustrating the use of the AbC-19(TM)
LFD in semi-quantitative format and showing the test line response
to be proportional to the amount of antibodies in an international
standard(1,2) .
The use of the score-card accessory alongside AbC-19(TM) LFD
will allow scientific communities to help further understand the
presence and strength of IgG neutralising antibodies following
infection and/or vaccination, a key indicator of protective immune
response and an additional tool to allow stratification of patients
in need of booster vaccinations.
Abingdon Health is preparing the CE-marking of this scorecard
accessory for the AbC-19(TM) LFD and ultimately, when the
scientific community determines the level of antibodies which infer
immunity, has the potential to add a 'cut-off' to the
score-card.
Recent research has highlighted that immuno-compromised
individuals generate lower levels of antibodies compared with
healthier people following two vaccine doses(3) , and there are
variations in vaccine-response between males and females(4) . A
study published on 30 August 2021 highlighted different responses
in patient cohorts when comparing the Moderna and Pfizer-BioNTech
vaccines(5) , with one study noting antibody levels start to reduce
at around 2-3 months(6) .
Determining the presence and strength of IgG neutralising
antibodies enables governments, individuals and businesses to make
more informed decisions about COVID-safety measures and vaccine
programme deployment to the most vulnerable. In areas of scarce
vaccine supply IgG neutralising antibody testing could be deployed
to stratify the population and direct vaccine to those with no or
limited immunity to the SARS-CoV-2 virus.
Abingdon Health notes the growing number of administrations such
as Hong Kong(7) that are now utilising post-vaccine serology
testing, in Hong Kong's case with a view to shortening quarantine
measures for inbound travellers and the Company believes that the
addition of the Semi-Quantitative scorecard accessory will aid
further deployment of on-site serology tests such as AbC-19(TM)
.
Chris Yates, Chief Executive Officer of Abingdon Health,
commented: "The launch of the semi-quantitative accessory to
AbC-19(TM) is an important addition to the tools available to
researchers as they qualify and measure the antibody level
appropriate to infer protective immunity. There is a lot of work
underway internationally to set a globally recognised standard
threshold and we welcome the establishment of an international
standard that will help governments manage their vaccine and
booster programmes. Devices such as the AbC-19(TM) help democratise
testing and allow individuals to know their own neutralising
antibody status, assess their own risk, and seek appropriate advice
when indicated."
References:
1.
https://www.abingdonhealth.com/news/abc-19tm-igg-lfd-successfully-used-semi-quantitively-to-monitor-vaccine-responses-to-variant-proteins/
2. https://www.sciencedirect.com/science/article/pii/S0163445321003637
3. https://www.bmj.com/content/374/bmj.n2098
4.
https://www.timesofisrael.com/israeli-research-finds-covid-19-antibody-levels-differ-between-men-and-women/
5. https://jamanetwork.com/journals/jama/fullarticle/2783797
6. https://www.ucl.ac.uk/news/2021/jul/vaccine-antibody-levels-start-wane-around-2-3-months
7. https://www.info.gov.hk/gia/general/202108/03/P2021080200985.htm?fontSize=1
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Shaun Dobson, Peter Steel, Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAKZGGLLVFGMZM
(END) Dow Jones Newswires
September 07, 2021 02:00 ET (06:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024